Keren Osman

1.9k total citations
38 papers, 1.2k citations indexed

About

Keren Osman is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Keren Osman has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 19 papers in Hematology and 16 papers in Oncology. Recurrent topics in Keren Osman's work include Multiple Myeloma Research and Treatments (17 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (13 papers) and Protein Degradation and Inhibitors (8 papers). Keren Osman is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (13 papers) and Protein Degradation and Inhibitors (8 papers). Keren Osman collaborates with scholars based in United States, Spain and Australia. Keren Osman's co-authors include Matthew D. Geller, Raymond L. Comenzo, Madhav V. Dhodapkar, Joseph Krasovsky, Yana Zhang, Carmen Martínez, Guillermo A. Herrera, Hani Hassoun, Yukio Ando and Kunihiko Hayashi and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Keren Osman

37 papers receiving 1.2k citations

Peers

Keren Osman
Bryan Ciccarelli United States
Alexandra Croockewit Netherlands
Chiara Gentilini Germany
Andreas Draube Germany
Simon Le Gallou France
Jeffrey J. Pu United States
Marc‐Steffen Raab Germany
Mingqing Zhu China
Dina Stroopinsky United States
Jakub Krejcik Denmark
Bryan Ciccarelli United States
Keren Osman
Citations per year, relative to Keren Osman Keren Osman (= 1×) peers Bryan Ciccarelli

Countries citing papers authored by Keren Osman

Since Specialization
Citations

This map shows the geographic impact of Keren Osman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keren Osman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keren Osman more than expected).

Fields of papers citing papers by Keren Osman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keren Osman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keren Osman. The network helps show where Keren Osman may publish in the future.

Co-authorship network of co-authors of Keren Osman

This figure shows the co-authorship network connecting the top 25 collaborators of Keren Osman. A scholar is included among the top collaborators of Keren Osman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keren Osman. Keren Osman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coffey, David G., Keren Osman, Adolfo Aleman, et al.. (2024). Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma. Journal for ImmunoTherapy of Cancer. 12(4). e008110–e008110. 5 indexed citations
2.
Ibrahim, Uroosa, Julio C. Chávez, Farhad Khimani, et al.. (2023). CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease. Clinical Lymphoma Myeloma & Leukemia. 23(10). 772–778. 1 indexed citations
3.
Ciccolini, Kathryn, et al.. (2023). CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma. Cureus. 15(9). e44542–e44542. 1 indexed citations
4.
Ciccolini, Kathryn, et al.. (2021). CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma. Blood. 138(Supplement 1). 4811–4811. 1 indexed citations
5.
Lentzsch, Suzanne, Raymond L. Comenzo, Jeffrey A. Zonder, et al.. (2020). Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. Journal of Clinical Oncology. 38(13). 1455–1462. 35 indexed citations
6.
7.
Lentzsch, Suzanne, Raymond L. Comenzo, Jeffrey A. Zonder, et al.. (2019). Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis. Amyloid. 26(sup1). 113–114. 1 indexed citations
8.
Pozo, Eduardo, José M. Castellano, Anubhav Kanwar, et al.. (2017). Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation. Journal of Cardiac Failure. 24(2). 78–86. 8 indexed citations
9.
Osman, Keren, Ajai Chari, Samir Parekh, et al.. (2016). Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma. Blood. 128(22). 3448–3448. 1 indexed citations
10.
Calvo, Verónica, Noa Biran, Keren Osman, et al.. (2015). Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment. BMC Cancer. 15(1). 444–444. 21 indexed citations
11.
Biran, Noa, Sundar Jagannath, Hearn Jay Cho, et al.. (2013). A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma. Blood. 122(21). 5392–5392. 9 indexed citations
12.
Chari, Ajai, Kevin Barley, Sundar Jagannath, & Keren Osman. (2012). Safety and Efficacy of Triplet Regimens in Newly Diagnosed Light Chain Amyloidosis. Clinical Lymphoma Myeloma & Leukemia. 13(1). 55–61. 12 indexed citations
13.
Elliott, Brian, Keren Osman, Eileen Scigliano, et al.. (2011). Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma*. European Journal Of Haematology. 86(4). 289–298. 28 indexed citations
14.
Osman, Keren, Brian Elliott, John Mandeli, et al.. (2010). Non‐myeloablative conditioning and allogeneic transplantation for multiple myeloma. American Journal of Hematology. 85(4). 249–254. 8 indexed citations
15.
Malone, Adriana K., John Mandeli, Celia Grosskreutz, et al.. (2009). Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization. Cytotherapy. 11(4). 457–463. 5 indexed citations
16.
Grosskreutz, Celia, Eileen Scigliano, Keren Osman, & Luis Isola. (2007). Graft Versus Host Disease After Stem Cell Allotransplantation With Low-Dose Total Body Irradiation, Fludarabine, and Antithymocyte Globulin. Transplantation. 84(5). 598–604. 5 indexed citations
17.
Chang, D., Keren Osman, John E. Connolly, et al.. (2005). Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. The Journal of Experimental Medicine. 201(9). 1503–1517. 337 indexed citations
18.
Dhodapkar, Madhav V., Joseph Krasovsky, Keren Osman, & Matthew D. Geller. (2003). Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy. The Journal of Experimental Medicine. 198(11). 1753–1757. 160 indexed citations
19.
Hedvat, Cyrus V., Raymond L. Comenzo, Julie Teruya‐Feldstein, et al.. (2003). Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. British Journal of Haematology. 122(5). 728–744. 52 indexed citations
20.
Comenzo, Raymond L., Yana Zhang, Carmen Martínez, Keren Osman, & Guillermo A. Herrera. (2001). The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden. Blood. 98(3). 714–720. 221 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bryan Ciccarelli Breakdown of academic impact, for papers by Alexandra Croockewit Breakdown of academic impact, for papers by Chiara Gentilini Breakdown of academic impact, for papers by Andreas Draube Breakdown of academic impact, for papers by Simon Le Gallou Breakdown of academic impact, for papers by Jeffrey J. Pu Breakdown of academic impact, for papers by Marc‐Steffen Raab Breakdown of academic impact, for papers by Mingqing Zhu Breakdown of academic impact, for papers by Dina Stroopinsky Breakdown of academic impact, for papers by Jakub Krejcik
Rankless by CCL
2026